Dr. Gasparetto on Selinexor and Daratumumab Combination in Multiple Myeloma

Cristina Gasparetto, MD
Published: Tuesday, Dec 19, 2017



Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses a phase Ib study of the combination of selinexor and daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma.

There are preliminary data demonstrating that selinexor resensitizes the myeloma cells to daratumumab, Gasparetto says.

This study was attempting to determine the dose of the combination. In the first cohort selinexor and daratumumab was given 60 mg/kg twice a week, explains Gasparetto.
 
SELECTED
LANGUAGE


Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses a phase Ib study of the combination of selinexor and daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma.

There are preliminary data demonstrating that selinexor resensitizes the myeloma cells to daratumumab, Gasparetto says.

This study was attempting to determine the dose of the combination. In the first cohort selinexor and daratumumab was given 60 mg/kg twice a week, explains Gasparetto.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x